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ABSTRACT
Pediatric high grade glioma (pHGGs), including sus-tentorial and diffuse intrinsic 
pontine gliomas, are known to have a very dismal prognosis. For instance, even an 
increased knowledge on molecular biology driving this brain tumor entity, there is no 
treatment able to cure those patients. Therefore, we were focusing on a translational 
pathway able to increase the cell resistance to treatment and to reprogram metabolically 
tumor cells, which are, then, adapting easily to a hypoxic microenvironment. To 
establish, the crucial role of the hypoxic pathways in pHGGs, we, first, assessed 
their protein and transcriptomic deregulations in a pediatric cohort of pHGGs and in 
pHGG’s cell lines, cultured in both normoxic and hypoxic conditions. Secondly, based 
on the concept of a bi-therapy targeting in pHGGs mTORC1 (rapamycin) and HIF-1α 
(irinotecan), we hypothesized that the balanced expressions between RAS/ERK, PI3K/
AKT and HIF-1α/HIF-2α/MYC proteins or genes may provide a modulation of the cell 
response to this double targeting. Finally, we could evidence three protein, genomic and 
metabolomic profiles of response to rapamycin combined with irinotecan. The pattern 
of highly sensitive cells to mTOR/HIF-1α targeting was linked to a MYC/ERK/HIF-1α 
over-expression and the cell resistance to a major hyper-expression of HIF-2α.
INTRODUCTION
Pediatric high grade gliomas (pHGGs), including 
diffuse intrinsic pontine gliomas (DIPGs), despite their low 
incidence, are the leading cause of mortality in pediatric 
oncology. Most pHGGs, localized in midline structures 
(thalamus and pons), are resistant to standard chemotherapy 
and harbor specific genomic alterations [1]. Studies 
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have begun to unravel new cancer pathways specific to 
pediatric gliomagenesis with the discovery of frequent 
mutations of histones in those pHGGs and their impact 
on prognosis [2–4]. Cooperative international efforts 
are aimed at developing new prognostic and predictive 
biomarkers, underlying specific biology of these childhood 
malignant gliomas. Among those, hypoxic features seem 
to be good candidates and a translational way to target 
the pHGGs not depending on their specific molecular 
rearrangements and epigenetic deregulation. In fact, the 
necrosis resulting from severe intra-tumor hypoxia and the 
aberrant microvasculature, usually associated with it, are 
common radiological and histological adverse prognostic 
criteria in high grade gliomas [5]. Intra-tumor hypoxia is 
known to favor angiogenesis, but also genetic instability 
through resistance to apoptosis and decreased DNA repair 
capacities, promoting a highly chemo- and radio-resistant 
phenotype to cancer cells [6–8]. As the tumor proliferates 
and grows, tumor cells have to adapt to high anabolic 
requirements and to extreme environmental conditions due 
to the incapacity of the tumor microvasculature to provide 
sufficient oxygen and nutrient supplies. This adaptation to 
hypoxia is sustained by a whole metabolic reprogramming 
of cancer cells through the preferential use of alternative 
metabolic pathways, favoring glycolysis (the “Warburg” 
phenotype), but also glutaminolysis or de novo lipogenesis 
[8–11].
Cancer metabolic reprogramming is now 
considered as a hallmark of cancer and is largely driven 
by oncogenic and tumor suppressor gene deregulations, 
involving notably TP53, AMPK, AKT, mTOR, HIF-1α, 
HIF-2α and/or MYC [12–16]. The glycolytic switch 
of tumor cells is mainly induced by the accumulation 
of HIF (Hypoxia-inducible Factor) proteins. HIFs 
form heterodimers, whose α subunit is stabilized 
under hypoxia through the inhibition of the oxygen-
dependent hydroxylases (PHDs) and its subsequent 
degradation by the proteasome. It can also be stabilized 
in normoxic conditions through different mechanisms 
of dysregulation at the transcriptional, translational and 
post-translational levels, leading to a pseudo-hypoxic 
phenotype [13–15]. HIF-1α and HIF-2α, the two most 
studied isoforms, activate numerous target genes. 
Noticeably, HIF-1α can activate the majority of genes 
involved in glycolysis, but, also, those involved in pH 
regulation, angiogenesis and metastatic progression 
[14, 15]. HIF-2α acts synergistically with HIF-1α to 
regulate many of these genes and its expression seems 
to be correlated with a more aggressive phenotype [16–
18]. TP53, MYC and AKT cooperate with the HIFs to 
synergistically induce glycolysis, while MYC is the main 
regulator of glutaminolysis [19, 20]. Moreover, HIF-
1α and HIF-2α have opposite effects on MYC or TP53 
stabilization. Therefore, the balanced expressions and 
interactions between those two isoforms are crucial for 
the understanding of the global cellular adaptation to 
hypoxia in cancers [19–21].
The other major regulator in hypoxia is mTOR. 
When mTOR is hyperactivated, it promotes HIF-1α 
protein activation, counteracting its degradation in 
normoxic conditions, leading to pseudo-hypoxia. Essential 
for tumor growth and survival, mTOR is also a sensor 
of nutrient level, favoring lipogenesis and inhibiting 
autophagy [21–23]. mTOR interacts with different protein 
partners, forming two distinct multiprotein complexes 
called mTORC1 (comprising RAPTOR and PRAS40) 
and mTORC2 (comprising RICTOR and PROTOR). 
mTORC1 is responsible for the downstream activation 
through its effects on S6K1 and 4EBP1, while mTORC2 
is responsible for the complete activation of AKT and is 
interacting with HIF-2. S6K1 is a serine/threonine kinase 
that phosphorylates the S6 protein of the 40S ribosomal 
subunit (phosphorylated S6 ribosomal protein (phospho-
S6RP or p-S6RP), which represent a specific surrogate 
of mTORC1 activation [24]. mTORC1 is positively 
regulated by the activation of PI3K/AKT and RAS/
MAPK signaling pathways and negatively regulated by 
PTEN and AMPK. Under hypoxia, mTORC1 is also 
inhibited by REDD1 and BNIP3, themselves induced by 
HIF-1α and tightly regulated through a negative inhibitory 
feedback loop via S6K1. The upstream degradation 
of IRS1 and the inactivation of RICTOR/mTORC2 
was also induced by S6K1 activation [24, 25]. mTOR 
inhibitors have shown limited efficacy in cancers, when 
used in monotherapy, partly due to the reactivation of 
AKT signaling pathway. This reactivation is mainly the 
consequence of the feedback loop induced by the residual 
HIF-1α expression and the balance between mTORC1 and 
mTORC2 [26–27].
The RAS-PI3K-mTOR pathway is altered in around 
25% of pHGGs, while PIK3CA/PIK3R1 and TP53 are 
mutated in less than 40% [3, 28]. However, AKT and 
ERK have been reported to be highly activated at the 
protein level in those pediatric brain cancers, while PTEN 
expression is lost in less than 50% of them [1-3, 28, 29]. 
Others biomarkers, like MYC or MYCN amplifications, 
occurring at lower frequency in pHGGs, were reported 
associated with histone mutations, especially in diffuse 
intrapontine gliomas (DIPGs) and in histone G34V 
mutated pHGGs [28–34]. In terms of hypoxia, pHGGs 
display the classical characteristics of microvascular 
proliferation and/or necrosis, associated with intra-tumor 
hypoxia, although HIF-1 or HIF-2 over-expressions 
have not been specifically studied, but involvement 
only suggested. In those highly resistant tumors to 
chemotherapy and radiotherapy, a strategy of bi-therapy 
consisting of inhibiting both mTORC1 by rapamycin and 
HIF-1α by irinotecan might be efficient by completely 
abolishing HIF-1α accumulation [35, 36] and was 
evaluated in a pediatric phase I on malignant refractory 
tumors (ClinicalTrials.gov Identifier: NCT01282697, 
results are currently finalized).
To establish, the crucial role of mTOR/HIF-
1α axis in pHGGs, we, first, assessed its protein and 
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transcriptomic deregulations in a pediatric cohort of 26 
pHGGs and in pHGG cell lines, cultured in both normoxic 
and hypoxic conditions. Secondly, based on the concept 
of a bi-therapy targeting mTORC1 and HIF-1α in pHGGs, 
we hypothesized that the distinctive genomic alterations 
of RAS/ERK and PI3K/AKT upstream signals and HIF-
1α/HIF-2α/MYC relative expressions would differentially 
modulate the response to this double inhibition and 
impact on specific metabolic changes. The final objective 
of this preclinical study was to determine the predictive 
metabolomic, transcriptomic and protein profiles of 
response to this therapeutic combination in pHGG in vitro 
models.
RESULTS
mTOR/HIF pathway is highly activated in 
pHGGs samples, which can be grouped in 
4 different hypoxia profiles
The first step of our study was to confirm the 
activation of mTOR-HIF-1/2α pathway in pHGGs. 
Therefore, we compared the RNA expression between 
14 low grade gliomas and 5 pHGGs, included in the 
whole cohort of 26 patients described in the material 
section (Figure 1A). The 5 pHGGs were over-expressing 
predominantly and significantly RAS, MAPK, AKT, 
VEGFA, VHL, HIF1 and RPS6KB1 genes, involved in 
hypoxia pathways. Furthermore, in the whole cohort 
of 26 pHGGs (all data presented in Figure 1B), the 
immunohistochemical assessment (Supplementary Data 
1) confirmed, as expected in the transcriptomic analyses, 
a frequent p-S6RP over-expression in 12/26 tumors and 
HIF-1α and HIF-2α over-expressions, respectively in 17 
and 11 tumors out of 26. Eight patients had a concomitant 
HIF-1α and HIF-2α positive stainings. Only, three patients 
had an isolated HIF-2α hyper-expression. Four subgroups 
(Figure 1C) might be distinguished regarding to the 
hypoxia surrogate markers expressed within samples. The 
group 1 may be characterized by the complete absence 
of HIF-1α/HIF-2α expression, but for half of them a 
predominant Pi3K/PTEN/AKT activation is present and 
for the other half an ERK/mTOR expression. In the group 
2, HIF-1α hyper-expression was linked in 5 patients 
to ERK/mTOR activation and in 4 cases to an isolated 
AKT hyper-expression. The presence of a HIF-2α hyper-
expression in the groups 3 and 4 seems to be associated to 
a PTEN/AKT activation in 7 cases and to mTOR hyper-
expression in 5 samples without any HIF-1α nor HIF-2α 
expressions.
In the 26 pHGGS (Figure 1B), the histone mutation 
was present in most of the DIPGs and the midline 
pHGGs. The G34V H3.3 mutation was rarer and only in 
hemispheric tumors (2 cases out of 10). There were no 
BRAF nor IDH1 mutations and only one tumor presents 
a PI3KCA mutation in exon 18. P53 rearrangement was 
frequently observed in 20 tumors. Frequent variations of 
copy number in PDGFRA and MET genes were found, 
whereas only one mutation of PDGFRA was diagnosed 
with Sanger sequencing in a midline pHGG.
The cell lines derived from patient tumors, TC35 
and TC68, were harboring the same genomic and protein 
abnormalities than in the tumor themselves.
All those data were underlining the presence of 
an activated mTor/HIF-1α/HIF-2α pathway throughout 
DIPGs and pHGGs. To go further and to understand the 
functional role of hypoxia in pediatric high grade gliomas, 
we focused on those pathways in pHGGs’ cell cultures.
Cell lines’ specific markers characterizing 
hypoxic conditions of culture
Hypoxia is clearly promoting mTOR signaling network 
activation in all cell lines (Figures 2A and 2B)
The impact of hypoxia on mTOR expression and 
its upstream PI3K-AKT and RAS-MAPK pathways 
was assessed, first, by immunoblot measures of their 
components in the cultures of the well-known and 
described cell lines, named KNS42, SF188 and UW479 
[37]. In normoxic conditions of culture, KNS42, which 
is characterized by genomic gain at the locus of PIK3CA, 
an activation of IGFR1 and NMYC pathways and a 
histone H3.3 G34V mutation, presented the highest 
activation of mTORC1, as shown by the phosphorylation 
of mTORC1 downstream substrates (p-S6RP and STAT3) 
on Figure 2A. This mTOR activation was associated 
with an inhibition of mTORC2, shown by the inhibitory 
phosphorylation of RICTOR (p-RICTOR) and a low 
level of phospho-AKT (p-AKT) on Figure 2B. Under 
hypoxia, KNS42 presented a mTORC1 inhibition, which 
impacted on the inhibitory feedback loop of AKT with an 
increase of p-AKT and an activated mTORC2 network, 
showed by the dephosphorylation of RICTOR (Figure 
2B). This feedback regulation was less prominent in the 
two other cell lines. Indeed, SF188 cell line, which is 
characterized by MYC amplification, NF1 deletion and 
a transcriptomic hyper-expression of PDGFRA and KIT, 
showed an intermediate level of mTORC1 expression, but 
a higher level of phospho-ERK (p-ERK). For this cell line, 
a further activation of ERK in hypoxia was correlated with 
a less important inhibition of S6RP (Figure 2A and 2B). 
UW479, carrying an IDH2 amplification associated with 
a hypermethylated phenotype, showed the lowest level 
of mTORC1 activation in normoxia. mTORC1 was also 
inhibited under hypoxia, but not associated with AKT 
nor ERK activations. Consistent with the role of mTOR 
inhibiting autophagy, the autophagy activity, reflected 
by the conversion of LC3B I in LC3B II, was especially 
present in UW479 in normoxia, where the lower level of 
mTORC1 induction was present. In hypoxia, the same 
autophagy levels than in normoxia were showed in the 3 
cell lines (Figure 2B). TC68 had the same protein profile 
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Figure 1: Status of  the mTOR/HIF-1α/HIF-2α/MYC axis and their upstream and downstream signals  in a patient 
cohort of 26 pHGGs. 1A: A transcriptomic analysis of hypoxic biomarkers in 5 pHGGs out of the 26 comparatively to 14 low grade 
gliomas (LGG) (the increased expressions are in red, the decreased expressions in blue and the normal one are in white). 1B: The global 
description of over-expression, genomic alterations or mutations in the 26 pHGGs performed by several techniques and targeting mTor/
HIF-1α axis deregulation (PI3KCA, MYC, PTEN, AKT, ERK, mTOR, HIF-1 and HIF-2) or pHGG/DIPG genomic characteristics. All 
normal results are in white boxes and each protein over-expression is in a corresponding color. 1C: Based on the individual patient profiles, 
four subgroups could be identified regarding the balanced expression of the hypoxia surrogate markers HIF-1α and HIF-2α.
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Figure 2: Impact of hypoxia (1% O2) on mTOR pathway activation, gene expression and proliferation in KNS42, 
SF188 and UW479 cell lines. Figure 2A and 2B: Comparative immunoblotting analyses of mTOR pathway activation in KNS42, 
SF188, UW479 and the patient-derived cell line TC68 cultured in both normoxic and hypoxic conditions. Figure 2C, 2D, 2E, 2F, 2G, 2H: 
Comparative transcriptomic analyses. The relative expressions of HIF-1/2α and MYC are described in Figure 2C. Unsupervised analyses 
showing the top genes significantly upregulated or down-regulated in response to hypoxia (1% O2) comparatively to normoxia conditions 
are described in Figure 2D. Gene set enrichment analysis testing HIFs gene targets is shown in Figure 2E, MYC gene targets in Figure 2F 
and genes involved in cell cycle progression in Figure 2G. Figure 2H is presenting the impact of hypoxia on the proliferations of KNS42, 
SF188 and UW479, assessed by a colorimetric proliferation assay using crystal violet and the calculation of doubling time. In the Figure 
2I, the effect on proliferation of siRNA transient transfection against HIF-1α, HIF-2α or both in SF188, KNS42 and UW479 cell lines in 
hypoxia. This effect was measured in triplicate and compared at 72 hours relatively to the control growth. *: p<0.05. ES: enrichment score; 
FDR: false discovery rate.
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than SF188 cell line in both culture conditions except 
for autophagy induction, which was absent. TC35 was 
matching the results of TC68 and SF188 (data not shown). 
Thus, the mTORC1 pathway seems to be gradually 
activated throughout those cell lines from the lower level 
in UW479 to the higher level in KNS42 in normoxia, 
whereas hypoxia is inducing gradually the mTORC2 
pathway with the lower level in KNS42 and the higher 
level in UW479.
HIF-1α is induced in hypoxic conditions in all cell lines, 
whereas HIF-2α hyper-expression is rarer
We compared the differential expression of HIF-1α 
and HIF-2α (or EPAS1) in all three cell lines (Figure 2A 
and 2C). In normoxia, no significant protein accumulation 
of HIF-1α or HIF-2α could be seen except a very slight 
increase in UW479 for HIF-2α protein (Figure 2A). The 
transcriptomic analyses confirmed the EPAS1/HIF2A 
over-expression in UW479 (Figure 2C). Under hypoxia, 
HIF-1α protein accumulation was inversely correlated 
to the level of mTOR activation, with the highest level 
in UW479 and the lowest HIF-1α expression in KNS42. 
HIF-2α protein was highly accumulated in UW479 
during hypoxia. Those protein levels were correlated with 
their mRNA expression levels in hypoxia, as shown in 
RNA expression (Figure 2C). As expected, MYCN was 
strongly over-expressed in KNS42 and MYC in SF188. 
The transcriptomic analyses of the response to hypoxia 
comparatively to normoxia determined the top genes 
mostly upregulated (n=50) and down-regulated (n=38) 
(Figure 2D). Amongst those, 27 are well-described 
and are HIF-1α targets, which are upregulated only in 
hypoxia conditions, confirming the hypoxic induction 
of HIF-1α. The GSEA analyses confirmed the strong 
enrichment in HIF1/2 target gene expression in all three 
cell lines when hypoxia is present (p<0.0001). Consistent 
with the HIF-1α inhibition of MYC target genes in 
hypoxia, a significant down-regulated expression of 
MYC target genes, involved in cell cycle progression, 
was observed in the three cell lines (Figure 2E, 2F and 
2G). As shown by the negative enrichment scores, there 
was a higher significance in SF188, where a spontaneous 
and known MYC amplification is present. Thus, the 
hypoxia is inducing HIF-1α expression in all cell lines, 
but, is clearly and significantly impacting on MYC 
target genes involved in cell cycle in SF188 and KNS42, 
where MYC or NMYC is spontaneously expressed in the 
standard condition of normoxia. HIF-2α is especially 
induced in UW479 cell line in absence of MYC/NMYC 
over-expression.
Cell proliferation is preserved even in hypoxia
Because of this negative effect on cell cycle gene 
expression, we looked at cells’ proliferation. KNS42 cells 
had no modification in their proliferation, whereas a slight 
inhibitory effect on the proliferation of SF188 and UW479 
was observed (Figures 2H) at 72h, based on the analyses 
of doubling time (p<0.05). To determine the respective 
impact of HIF-1α and HIF-2α RNA expression on the 
proliferative capacities of those cell lines under hypoxia, a 
transient transfection was performed with siRNAs against 
HIF-1α, HIF-2α and the combination of both (Figure 2I). 
The inhibition of HIF-1α and/or HIF-2α contributed to a 
proliferation inhibition in UW479. A 75% decrease in case 
of HIF-1α or HIF-2α inhibition was observed and a higher 
significantly inhibition with the combination of both 
siRNAs was present (p<0.05). In KNS42 and SF188, the 
inhibition of HIF-1α had no significant anti-proliferative 
effect. The inhibition of HIF-2α led to a surprising and 
moderate effect in SF188 (50%, p<0.05), while a stronger 
effect in SF188 was observed with the combined inhibition 
leading to an 80% growth inhibition (p<0.05). This 
inhibitory effect in SF188 is predominantly observed with 
HIF-2α and efficient in hypoxia conditions, where MYC 
target genes are clearly and significantly inhibited by 
hypoxia itself and subsequent to HIF-1α induction (Figure 
2F and 2G). Therefore, the unique inhibition of HIF-1α is 
probably increasing the MYC target gene expression and 
promoting a partial proliferative effect in SF188, whereas 
the combined inhibition is more decreasing the MYC 
target genes’ effects on cell proliferation.
In conclusion, cell proliferation seems to be 
preserved in hypoxia conditions
Hypoxia is contributing to specific metabolic switches 
according to the initial induced protein profiles
In order to understand the changes in metabolic 
fluxes associated with hypoxia, the metabolomic profiles 
were compared to gene expression and to the protein 
profiles of KNS42, SF188 and UW479 (Figure 3). A 
significant accumulation of lactate was evidenced in 
all three cell lines in hypoxia, correlated with an up-
regulation of the glycolysis genes at the mRNA level 
(Figure 3A1 and 3A2). SF188 was characterized by the 
highest accumulation of lactate in hypoxia, which was 
concordant with the accumulation of glutamate, associated 
with the highest basal up-regulation of glutaminolysis 
gene expressions (Figure 3B2). The metabolomic 
profile of SF188 in Figure 3D confirmed with the 
accumulation of glutamine, aspartate, alanine and glycine 
the glutaminolysis activation. The glycine, its metabolic 
derivatives (creatine and phosphocreatinine), alanine 
and taurine were also accumulated in SF188 and were 
the witnesses of a concomitant over-expression of the 
serine/glycine biosynthetic pathway genes (Figure 3C and 
3D). In KNS42, the accumulation of glutamine, alanine, 
taurine and glycine reflected the concomitant activation 
of glutaminolysis and serinolysis in both conditions 
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of culture, but, comparatively to SF188 cell line, the 
activation of serinolysis was predominant in hypoxia, 
as the glycine and glutamine levels were persistent and 
higher (Figure 3A2 and 3D). Lipid storage and triacyl-
glycerol synthesis pathways were significantly induced by 
hypoxia in KNS42, where a concomitant up-regulation of 
lipogenesis regulators and the genes of lipid biosynthesis 
was present (Figure 3C2). The increase of the PCho:GPC 
(phosphocholine/glycerophosphocholine) ratio, reflecting 
an increase in phosphatidylcholine (PtCholine) synthesis 
Figure 3: In vitro metabolomic analyses of KNS42, SF188 and UW479 cell lines cultured in hypoxia (1% O2). Each 
metabolic pathway was comparatively analyzed in terms of metabolite accumulation by HRMA NMR spectroscopy (concentrations 
expressed in nmol/mg) and in terms of gene expression by microarrays with GSEA analysis. Glycolysis was analyzed in terms of lactate 
accumulation and gene expression (Figure 3A1, 3A2), glutaminolysis in terms of glutamine and glutamate accumulations and gene 
expression (Figure 3B1, 3B2), the lipid synthesis and degradation pathway in terms of PCho:GPC ratio and gene expression (Figure 
3C1, 3C2), the amino-acid, creatine and gluthatione (GSH) pathways in terms of metabolite accumulations (Figure 3D). Ala: alanine; 
Asp: aspartate; Val: valine; Ile: isoleucine; Lys: lysine; Thr: threonine; Gly: glycine; Cr: creatine; PCr: phospho-creatine; Naa: N-acetyl-
aspartate; Tau: taurine; Gsh: gluthatione; PCho: phosphor-choline; GPC: glycerophosphocholine; PtCholine: phosphatidyl-choline.
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(Figure 3D), confirmed the induced lipogenesis in 
KNS42. In UW479, in both conditions of oxygenation, 
the only major metabolic pathway was lipolysis, which 
was characterized by the PCho:GPC ratio decrease 
concomitantly with the induction of PtCholine degradation 
genes (Figure 3C and 3D) and the up-regulation of genes 
involved in lipolysis.
In conclusion, SF188, where MYC and mTORC1/p-
ERK/HIF-1α were overexpressed, was characterized by 
a glycolysis and a glutaminolysis induction in hypoxia. 
For KNS42, where NMYC and mTORC1/p-AKT were 
overexpressed, a predominant glycolysis, serinolysis and 
lipogenesis induction was present. Finally, the UW479, 
mainly characterized by its spontaneous HIF-2α hyper-
expression, had a major lipolysis induction in hypoxia 
conditions.
Sensitivity to mTOR/HIF-1α inhibition 
correlates positively with AKT/PI3K activation 
and negatively with HIF-2α accumulation
Proliferation impact of those targeted treatments
The GI50 values are reported in Figure 4A for 
irinotecan and Figure 4B for rapamycin. They were 
obtained for small doses of rapamycin (ranging from 0.3 
to 30.1 nM in normoxia and 5.8 to more than 1000 nM 
in hypoxia). However, the effect on proliferation was 
moderate in all three cell lines (Figure 4C). In normoxia, 
UW479, the most sensitive cell line to rapamycin, showed 
a maximal plateau effect of 50% from a dose of 1 nM. 
SF188, harboring intermediate sensitivity to rapamycin, 
showed the same response with a decrease rate of 50% 
from 5 nM, whereas KNS42, the most resistant, reached 
a maximal 50% growth inhibition for a dose of 100 nM 
of rapamycin. In hypoxia, the same effect (decrease of 
50% of cell proliferation) was obtained for higher doses 
of rapamycin. UW479 was highly resistant to irinotecan 
in normoxia and hypoxia. With a GI50 around 1.5 μM in 
normoxia and hypoxia, SF188 was the most sensitive to 
irinotecan, while KNS42 showed a moderate response.
In order to assess the potential synergy of the 
combination, we calculated the combination index of both 
drugs with the Chou and Talalay method (rapamycin: 
5, 10 and 50 nM and irinotecan: 1, 5 and 10 μM) (Figure 
4D). A quite constant synergism in drug combinations 
was observed in SF188 cells, where the smallest doses of 
rapamycin and irinotecan (5 nM and 1 μM, respectively) 
in both normoxia and hypoxia were efficient. In KNS42, 
a clear synergy (CI<0.9) could be obtained in normoxia 
with the combination but only with the lower doses of 
irinotecan independently from rapamycin doses. The higher 
dose of irinotecan combined with rapamycin only showed 
an additive effect, whereas, in hypoxia, a synergism could 
be obtained by increasing the doses of rapamycin and 
irinotecan. Therefore, the optimal doses of those drugs in 
both oxygen conditions might be 10 nM of rapamycin and 5 
μM of irinotecan in KNS42 cells. In UW479, overexpressing 
HIF-2α, a higher dose of irinotecan 10 μM with rapamycin 
from 10 nM was necessary to obtain a regular synergism 
in both culture conditions. So, the common doses, which 
might give in most of the cells (SF188 and KNS42) a 
“regular” synergism, were 10 nM of rapamycin and 5 μM of 
irinotecan. We considered the UW479 as the less sensitive 
cells or even the resistant cells to the treatment combination.
We tested those doses in both conditions in TC68 
and TC35 (presenting K27M histone H3.3 mutations). 
TC68 cells, overexpressing concomitantly MYC, p-AKT 
and HIF-1α proteins (Figure 1B, the DIPG tumor with 
the bar), close to the protein profile of SF188 cells, were 
showing an equivalent sensitivity as SF188 cells. The cell 
viewing with Incucyte© technology in TC68 showed a 
high decrease (automated calculations) of neuropsheres’ 
size with rapamycin, irinotecan and the combination 
(Figure 4E and 4F). TC35, overexpressing mTORC1 and 
p-AKT as in KNS42 cells (Figure 1B, the pHGG tumor 
with the star), presented an intermediate response in terms 
of growth control.
The bitherapy is clearly effective in SF188 cells 
considering protein responses (Figure 5)
KNS42 response to rapamycin was characterized 
in normoxia and hypoxia by a strong activation of 
mTORC2 as shown by the phosphorylation of AKT with 
a concomitant dephosphorylation of RICTOR (Figure 
5A). P-AKT was not induced in SF188 and UW479 and 
even slightly repressed. As expected, the downstream 
substrate of mTORC1, S6RP, was importantly repressed 
by rapamycin in all three cell lines. P-ERK was strongly 
induced by rapamycin in SF188 and particularly in 
hypoxia, while it was only slightly induced in KNS42 
and not in UW479. P-AKT or p-ERK expressions were 
not influenced by irinotecan alone or in combination 
with rapamycin (Figure 5A). HIF-1α accumulation was 
strongly repressed under hypoxia by rapamycin in KNS42 
and only partially in SF188 and UW479. HIF-2α was not 
repressed in KNS42 under hypoxia, but was repressed in 
SF188 and more slightly in UW479. Noticeably, there was 
no inhibition of HIF-1α nor HIF-2α protein accumulations 
in any of these cell lines by irinotecan monotherapy. In 
UW479, an increase of HIF1 and HIF2 accumulation 
could be observed with the combination of the 2 drugs. 
At the mRNA level, only, few HIF-1/2α target genes were 
significantly and differentially inhibited by rapamycin 
in KNS42 and SF188 (Figure 6A), while no significant 
down-regulation, for example in SLC2A3, PGK1 or PDK1 
expressions, could be observed in UW479. The increase 
of HIF-1α/HIF-2α in UW479 cells with the bitherapy 
might explain the resistance of those cells to this mTOR/
HIF-1α targeting. The major role of HIF-1α and HIF-2α in 
UW479 cells was already underlined in Figure 2I, where 
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Figure 4: Efficacy of rapamycin, irinotecan and the combination of both in terms of anti-proliferative effect measured 
at 72 hours from treatment in normoxic and hypoxic conditions in the 3 cell lines and in TC68/TC35. This anti-proliferative 
effect was measured using a crystal violet colorimetric proliferation assay in the 3 cell lines and a trypan blue exclusion assay with 
automated counting of cells in TC68 and TC35. The 50% growth inhibition (GI50) values (95% CI) are reported for irinotecan in Figure 
4A and for rapamycin in Figure 4B. Proliferation curves are reported in Figure 4C and combination indexes (CI) in Figure 4D. For TC68, 
the effect of drugs on neurosphere formation is described in Figure 4E (phase contrast microscopy) and the effect on proliferation in Figure 
4F for TC68 and TC35.
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Figure 5: Cell effects of rapamycin, irinotecan and the combination and impact on the mTOR-HIF-1/2α pathway in 
KNS42, SF188 and UW479 in both normoxic and hypoxic conditions. The immunoblotting analyses of the protein expressions 
are presented for the cleaved PARP, phospho-H2AX and LC3B as markers of apoptosis, double strand breaks and autophagy, respectively, 
and for the phosphorylated forms of RICTOR, AKT, ERK and S6RP as markers of mTOR pathway and HIF-1/2α protein accumulations in 
Figure 5A. The Figure 5B is illustrated the quantification of western blot analyses (c-PARP/control ratio and LC3BI/LC3BII ratio). The 
Figure 5C is presented cleaved-caspase 3 western blot analysesfor each cell line and the significant gene set enrichment analyses testing 
apoptosis genes in SF188 and autophagy pathway in UW479.
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UW479 cells were dramatically sensitive in terms of cell 
proliferation to direct siRNA targeting of those proteins.
The cleaved-PARP, witness of apoptotic cells, was 
only present in KNS42, when treated with irinotecan in 
normoxic conditions, along with a concomitant increase 
of DNA double strand breaks (increase of phosphoH2X) 
and autophagy (presence of LC3BII) was increasing in 
case of rapamycin treatment in normoxia (Figure 5A and 
Figure 6: Effects of rapamycin, irinotecan and the combination of both on metabolism gene expression in KNS42, SF188 
and UW479. The results of glycolysis pathway deregulation are presented in Figure 6A. The gene deregulations in the glutaminolysis 
pathway are described in Figure 6B and the effects on phosphatidyl-choline degradation pathway are showed in Figure 6C.
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5B). Treatment of SF188 cells showed apoptotic cells in 
all conditions of culture and treatment, confirming SF188 
as the more sensitive cell line to mTOR/HIF-1α targeting. 
This expression of cleaved-PARP was completely 
matching phosphoH2AX expression and the cleaved-
caspase protein expression, whereas autophagy was 
constant and not depending on the type of treatment nor 
culture conditions (Figure 5B and 5C). The GSEA analyses 
confirmed the apoptosis pathway involvement in SF188 
(Figure 5C) and the constantly induced autophagy was 
confirmed at mRNA levels with the spontaneous increased 
expressions in all conditions and treatments of autophagy 
genes, like ULK2, ATG14 or ATG12 (Supplementary Data 
2). UW479 cells seem, as already showed above, to be 
resistant to mTOR and HIF-1α targeting with a highly 
induced autophagy especially under hypoxia and without 
any visible apoptotic cells (Figure 5A, 5B and 5C).
Resistance to rapamycin and/or irinotecan inhibition 
on cell metabolism was based on an induced lipolysis
The glycolytic pathways upregulated in all cell 
lines under hypoxia were poorly impacted with the 
targeting of mTOR/HIF-1α in the cells. In fact, the 
majority of glycolysis genes were not down-regulated, 
as well as the protein expression of GLUT1 (SLC2A1), 
a downstream target of HIF-1α (Figure 5A, 6A and 
7A). The metabolomic analyses reveal no significant 
decrease in the glucose or lactate metabolites, when the 
cells were treated with rapamycin or irinotecan during 
normoxia or hypoxia (Figure 7A). An increased level of 
glucose was even present in the resistant UW479 cells 
in both conditions and with all treatments. In the most 
sensitive cells, SF188, the only significant glycolytic 
metabolite was an increased level of succinate. The 
phospho-creatine:creatine ratios increased when treated 
KNS42, whereas this ratio was intermediate in SF188 
and decreased completely in UW479. So, the response to 
treatment in SF188 and in KNS42 seems to be an excess 
of glycolysis with an increase of phosphocreatine, even the 
ATP production seems not to be significantly increasing 
during metabolomic assessment. In parallel, the level of 
ROS regulation metabolites in Figure 7 was significantly 
increasing in responding cells to almost all drugs in both 
conditions and was not changing in the resistant UW479 
line.
Nevertheless, glutaminolysis was strongly inhibited 
by rapamycin in SF188, as shown by the inversion of the 
glutamate/glutamine ratio (<0.25) and the down-regulation 
of glutaminolysis genes (Figure 6B and 7). Irinotecan 
monotherapy had an inhibitory effect on glutaminolysis in 
SF188 and, only, in normoxia. In SF188, the combination 
of both drugs led to a further glutaminolysis inhibition 
in both cell lines and in both culture conditions and was 
confirmed by the accumulation of aspartate, alanine, 
valine, isoleucine, lysine and glycine (Figure 7A). In 
KNS42, no inhibition was detected and, only, a moderate 
inhibition was underlined in UW479 cells with a slight 
inversion of the glutamate/glutamine ratio (0.69).
For the phospholipid pathway usually influenced 
by the modulation of mTOR, the decrease of the 
phosphocholine level was present in case of UW479 
resistant cells to bitherapy. Correlating with these 
Figure 7: Effects of treatment on metabolite accumulation. The results are expressed relatively to control and a significance 
(p<0.05) was present when compared cell lines and culture conditions. In Figure 7A, the changes are shown in red color when the 
metabolites are increasing, in green color when they are decreasing and in white when the expression was normal. 
(Continued )
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Figure 7 (Continued ): In Figures 7B and 7C, the cartoons are describing the metabolites and their pathway deregulation (yellow arrows 
in normoxic culture, green arrows for hypoxic conditions). The figure 7B is representing the specific metabolite deregulation in the more 
sensitive cells (SF188 cell line) and the figure 7C in the more resistant line (UW479 cell line).
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observations, some phospholipases at the origin of the 
generation of GPC were down-regulated at the mRNA 
level particularly in UW479 under hypoxia (Figure 6C) 
and confirmed the increase of the lipolytic pathways. On 
the contrary, the levels of both phosphocholine and GPC 
were increasing in SF188 cells to combined therapies 
with a probable inhibition of the residual lipolysis in 
the cells.
The Figure 7B and 7C are summarizing the 
metabolomic signatures observed after concomitant 
inhibition of mTor/HIF1 axis in the more sensitive cells, 
SF188, in both culture conditions and in the resistant 
UW479 cells. In fact, the more sensitive cells to the 
combination of rapamycin and irinotecan were defined 
with an excess of glycolysis and a high inhibition of 
glutaminolysis and lipolysis. In the resistant cells, UW479, 
the metabolic signature was characterized mainly by the 
absence of inhibition in the lipolytic pathways.
The in vivo translation into patient samples 
showed comparable profiles in protein 
expression and culture
The immunohistochemical analyses in the 26 
patients’ tumors screened different patient subgroups 
based on the AKT/ERK and HIF-1α/HIF-2α balances. In 
those analyses, we could isolate, as in UW479 cells, a 
small subgroup with an isolated HIF-2α over-expression. 
It represents a very few number of patients in the group 
3 (Figure 1C), only 2 patients had those protein criteria. 
The SF188 profile is typically associating a concomitant 
p-ERK/MYC hyper-expression with a HIF-1α over-
expression or normal expression, as in the groups 1 and 2 
and in the group 4. Among the 8 MYC amplified tumors, 
there are 4 patients corresponding to the complete SF188 
protein profile. In the same groups, KNS42 profile could 
be also outlined in 3 tumors, if we are combining the 
p-AKT hyper-expression plus mTor expression without 
any HIF-2α expression. Nevertheless, we might also 
have a less restricted protein profile based on the cell 
behavior after combined treatment, as the slide of 
the tumor is representing an unknown timepoint and 
spacepoint in the tumor itself. We could, then, base our 
tumor selection for sensitivity on the balance between 
p-AKT, p-ERK, MYC or mTor, which concomitantly 
or independently are modulating the sensitivity to 
rapamycin and irinotecan, and in the absence of an 
isolated HIF-2α over-expression. This sensitive group 
is, then, reaching one third of the tumors. To afford a 
partial confirmation of the drug sensitivity, in patient-
derived cell lines, we also tested the double inhibition 
of mTOR and HIF-1α. In TC68, bearing H3.3 (K27M), 
TP53 mutations and a similar protein profile to SF188, 
cells’ response was similar to SF188 response in both 
conditions and confirmed the therapeutic potential of this 
combination in sensitive pHGGs.
DISCUSSION
As no real data on the role of hypoxia in pHGGs 
are published up to date, our first step in this work was 
to analyze tumor samples of pHGG and DIPG to screen 
if biomarkers involved in mTOR/ HIF-1α pathway were 
upregulated. Our data showed a major activation and/
or over-expression of all markers justifying a further 
study in pHGGs cell lines testing the hypoxia conditions 
themselves and the concomitant inhibition of mTor and 
HIF-1α. Another argument to target such pathway was 
the fact that initiating tumor cells are often localized in 
hypoxic niches within tissues, usually restarting at relapse 
even after a curative treatment. Recent publications are 
considering those cells as the key in the tumor initiation 
and the growth maintenance of a number of pediatric brain 
tumors including the high grade gliomas, where hypoxia 
inducible factors (HIFs) seem to play key roles in those 
cells [38, 39].
In the cell study, we showed, first, that the 
dysregulation of MYC/MYCN and the mTOR/HIF 
pathway determined the responses of pHGG cell lines 
to hypoxia and their response to the pharmacological 
inhibition of mTOR and HIF-1α. As mTOR is known to 
be physiologically inhibited by hypoxia, the first question 
was to understand the benefit of a further inhibition by 
rapamycin in hypoxic tumors based on the oncogenic and 
metabolic adaptations adopted by the cells to survive and 
proliferate in those conditions.
In KNS42, the induction by hypoxia of AKT, 
HIF-1α and HIF-2α in conjunction with the basal 
MYCN over-expression lead to a complete metabolic 
reprogramming through the main activation of glycolysis, 
glutaminolysis and lipogenesis [40]. Compared to the 
other cell lines, KNS42 was the only one to induce the 
“de novo” lipogenesis pathway under hypoxia correlating 
with the best adaptation to hypoxia. The upregulation of 
the transcription factor SREBP-1, master regulator of 
lipogenesis sustained this specific induction in KNS42 
RNA expression profiles. Although supposed to be under 
the positive control of mTORC1, several studies have 
highlighted the role of mTORC2 and AKT in activating 
lipogenesis through SREBP-1, linking this reactivation to 
the best metabolic adaptation to hypoxia for tumor cells 
[41–44]. The inhibition of mTORC1 and mTORC2 seem 
to impact on this metabolic adaptation and could help even 
in hypoxia to stop cell proliferation [45]. In comparison, 
AKT was not activated by hypoxia in SF188 and UW479, 
consistent with their down-regulation of SREBP-1 and 
lipogenesis genes.
SF188 showed, as already described, an 
important basal activation of glutaminolysis promoted 
by MYC amplification [46, 47]. In the cell lines using 
glutaminolysis, this convergence towards glutamate 
utilization is used to fuel the TCA cycle to produce 
energy and sustain lipogenesis [47]. The response of 
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SF188 to hypoxia was characterized by a high activation 
of glycolysis and reductive glutaminolysis along with 
a moderate HIF-1α and a slight HIF-2α accumulation. 
Promoting proliferation and survival, a predominant 
p-ERK activation could be observed in SF188 and related 
to its NF1 deletion.
In normoxia, the third cell line, UW479, was 
characterized by low levels of mTOR, ERK and AKT 
expressions, without MYC or MYCN dysregulation. It 
was also characterized by higher level of free amino acids, 
potentially resulting from its higher basal autophagic 
activity and is usually inducing mTor expression [48, 
49]. Moreover, the lipases MAGL and LPL were over-
expressed in UW479 and are well-known markers of 
aggressiveness in cancer [50]. Therefore, UW479 may rely 
on lipolysis and autophagy to sustain its energy demand 
and its adaptation to hypoxia, promoting this cell as a 
highly resistant one. In the absence of MYC or NMYC 
dysregulation, the very high accumulations of HIF-1α 
and HIF-2α observed in UW479 under hypoxia were 
correlated with a less predominant activation or addiction 
to glycolysis and glutaminolysis.
It is likely that of all these factors act synergistically 
in the promotion of the specific metabolic phenotype 
of each cell in normoxic and hypoxic conditions and 
may result from a subtle balance. Interestingly, HIF-1α 
and HIF-2α act in opposite ways to regulate cell cycle 
progression, by inhibiting (for HIF-1α) or promoting (for 
HIF-2α) MYC/MYCN stabilization or transcriptional 
activity [20, 21].
In KNS42 and SF188 in which MYC/MYCN was 
deregulated and HIF-2α really slightly expressed, most of 
the genes involved in cell cycle progression were down-
regulated under hypoxia. Nevertheless, in UW479, in 
which HIF-2α was highly expressed, this latter was not 
able to promote proliferation in the absence of MYC/
MYCN deregulation and counteract the effect of mTOR 
inhibition. In contrast, KNS42 and SF188 were able to 
maintain the same proliferation rates, suggesting that 
these cells have adapted to the hypoxia-induced effects 
on MYC/MYCN through AKT and ERK reactivations or 
diverse genomic alterations like the CDK4 and CCND2 
gene amplifications seen in SF188. Indeed, the specific 
inhibition of HIF-1α or HIF-2α by siRNA interference 
had no significant impact on proliferation in KNS42 or 
SF188, but the combined inhibition of both negatively 
did, confirming their alternative role to promote survival 
and proliferation [16, 20]. These results suggest that, 
in the context of a MYC/MYCN dysregulation, the 
unique inhibition of HIF-1α is not efficient to control 
cell proliferation, whereas HIF-2α targeting seems to be 
efficient in MYC amplified cells as already described 
in other cancers [51]. It also suggests that HIF-2α can 
modulate proliferation even at low levels of expression, 
but it may depend on a complex transcriptional synergy 
with HIF-1α [15, 19, 21, 51]. Interestingly, in absence of 
MYC/MYCN deregulation, in UW479, the inhibition of 
HIF-1α and HIF-2α was sufficient to inhibit proliferation, 
confirming their role as drivers of tumor cell survival 
and might reverse the potential resistance to concomitant 
mTor/HIF-1α inhibition in case of highly HIF-2α over-
expression.
To go further, helping to describe precise profiles 
linking genomics and metabolomics to treatment response 
[52], we performed such combined analyses in those in 
vitro models to establish distinct profiles of response to 
rapamycin and irinotecan. While SF188 and UW479 were 
relatively sensitive to rapamycin, KNS42 was resistant. 
Similarly to the hypoxia-induced mTOR inhibition, the 
pharmacological inhibition of mTOR by rapamycin led 
to a strong feed-back activation of mTORC2 and AKT 
in KNS42. As glycolysis, glutaminolysis and lipogenesis 
processes were not inhibited by small doses of rapamycin 
and even promoted under hypoxia in KNS42 despite a 
strong inhibition of HIF-1α accumulation; it is likely 
that HIF-2α and AKT might be drivers of resistance 
to rapamycin in this cell line. A recent publication 
also described MYCN as a regulator of cell metabolic 
adaptation independently from HIF-1α throughout the 
inhibition of NDRG family [53]. In fact, NDRG1 is 
repressed under hypoxia in KNS42 and activated by 
HIF-1α induction in SF188 and UW479. These results 
are correlated with the modest anti-proliferative effects 
obtained with siRNAs against HIF-1 in KNS42. In SF188, 
the modest activity of rapamycin could be related to ERK 
activation and the subsequent less inhibition of mTOR. 
A strong anti-glutaminolytic effect was associated with 
rapamycin treatment response in SF188. The sensitivity 
to rapamycin was also correlated with the accumulations 
of aspartate and glycine, previously described and 
correlated to a decrease of NTP/dNTP synthesis [54]. 
An increase of free amino acids was also observed in the 
rapamycin sensitive cell lines and could be related to a 
global inhibition of protein synthesis and/or an increase of 
autophagy due to mTOR inhibition [54].
The PCho:GPC ratio was the best to recapitulate the 
sensitivity to irinotecan. Its increase was related to high 
proliferation rates and invasiveness in glioma tumors, 
as in UW479, whereas the diminution of this ratio was 
correlated with response to therapy and considered as a 
surrogate marker for growth inhibition, as observed in 
SF188 and KNS42 sensitive cell lines [55]. Irinotecan, 
known as a TOP1 inhibitor, was also reported to inhibit 
HIF-1α gene transcription [35, 36, 56]. In our cell lines, 
irinotecan seemed to have only modest effects on HIF-1α 
expression. Nevertheless, a synergy could be evidenced 
with the combination of both drugs in the three cell lines, 
even at low doses. Interestingly, this complex synergy 
was significantly recapitulated by metabolomic changes, 
but also by protein or transcriptomic variations and 
confirmed the increased efficacy especially in SF188. 
The most complete response was traduced in SF188 
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by concomitant glutaminolysis, amino-acid and lipid 
synthesis inhibitions.
Most patient tumors seem to present an over-
expression of either AKT or ERK, when analyzed by 
immunohistochemistry. The association with a MYC 
amplification was present in one third of the population 
recapitulating closely the SF188 protein profile. In 
addition, p-AKT/mTor was evidenced in another third and 
assimilated to KNS42 profile. Only 3 tumors had a HIF-
2α over-expression without an alteration in p-ERK/mTor 
pathway and could be considered as potential resistant 
patients to our combination. The remaining tumors are 
characterized by a transitional profile described only in 
the sensitive cell lines. Finally, as could be expected in 
their protein signature, the patient derived cell line, TC68 
showed a good sensitivity to rapamycin plus irinotecan 
treatments, as well as in SF188 cells, and TC35 presented 
an intermediate response to the combination as well 
as in KNS42 cell line. Despite the limitations of the in 
vitro models, these genotypes seem to be associated 
with specific intrinsic responses, which should be taken 
into consideration for resistance prediction and patient 
treatment.
In conclusion, using an in vitro model of hypoxia, 
susceptible to mimic more closely the in vivo hypoxic 
tumor conditions, we depicted metabolomic profiles of 
response to the combination of rapamycin plus irinotecan, 
determined by a balance between upstream signals 
in MYC and mTOR/HIF-1/2α pathways. Hence, we 
confirmed the high chemo-resistant phenotype driven 
by hypoxia through the induction especially of HIF-2α. 
We also showed that in the presence of MYC or NMYC 
dysregulation, the unique inhibition of HIF-1α was not 
sufficient and necessitated a combined approach. These 
profiles, which can be easily identified by IHC and 
MRI spectroscopy could be finally used as predictive 
biomarkers in future patients treated with the combined 
therapy.
MATERIALS AND METHODS
Patients
20 pediatric patients with supratentorial pHGGs and 
6 with DIPG were included in the study after obtaining 
written informed consents. Aged from 8 to 19 years, they 
were treated between January 2005 and December 2013 
in Strasbourg’s University Hospital. The research protocol 
was validated by the local institutional ethic committee for 
human tissue experiments. The anonymized fresh-frozen 
or paraffin-embedded tumor samples were collected at 
diagnosis from surgical biopsy or resection and stored 
at the Biological Resource Centre (CRB) of Strasbourg 
(declaration number DC-2013-1826, May 2013).
Cell lines and reagents
Three cell lines, SF188, KNS42 and UW479, were 
already established and tested in multiple assays. TC68 
is a new tumor-derived cell lines obtained from a DIPG 
tumor with specific molecular characteristics described in 
Figure 1B (this tumor is marked in the histone mutation 
raw with a bar). A second primary cell line TC35 was also 
developed from a thalamic grade 4 glioma with a histone 
K27M mutation (this tumor is marked with a star on the 
histone mutation raw in the same Figure 1B).
Cell lines were cultured in DMEM/F-12 
GlutaMAX™ (Gibco®) with 10% FBS. TC68, as well as 
KNS42 and SF188, grew as neurospheres with a FBS-
free medium supplemented with B27 (Gibco®), FGF 
(Millipore®) and EGF (Gibco®). TC35, as well as UW479, 
are adherent cell lines. All cells were maintained at 37°C in 
normoxic (21% O
2
) or hypoxic (94% N
2
, 5% CO
2
, 1% O
2
) 
conditions in a Sanyo® incubator. Rapamycin was obtained 
from LC Laboratories (Woburn, USA) and irinotecan from 
Sandoz (Levallois-Perret, France). For hypoxic analyses, 
a prior progressive adaptation to hypoxia was realized to 
reach a final 1% concentration.
Proliferation and growth inhibition assay
Proliferation and growth inhibition were 
determined using a crystal violet staining viability assay 
with optical spectrophotometry analysis as previously 
described [57]. For each drug, the GI50 (dose leading to 
50% of the maximal growth inhibition effect on cultured 
cells) was assessed at 72 hours after treatment exposure. 
Values of optical density are reported as means+/-SD 
(standard deviation) obtained from three independent 
experiments.
Protein analyses
Antibodies
For immunohistochemical, immunocytological and/
or immunoblotting assays, the following antibodies were 
used against: αβ tubulin, LC3B, phospho-p44/42 MAPK 
(ERK1/2) (Thr 202, Tyr 204), phospho-RICTOR (Thr 
1135), phospho-S6RP (Ser 235) and purchased from Cell 
Signaling Technology (Ozyme, St-Quentin-en-Yvelines, 
France). GLUT1, HIF-1α, HIF-2α, PARP, cleaved PARP, 
phospho-STAT3 (Tyr705) were purchased from Abcam 
(Paris, France), and phospho-H2AX (Ser 139) from 
Merck Millipore (Darmstadt, Germany). The histone 
status was assessed by immunohistochemical staining 
with an antibody detecting the loss of nuclear expression 
of the trimethylated lysine 27 (H3K27me3) in histone H3 
(Diagenode, Belgium).
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Western blot analyses
Proteins were extracted after 24h of drug exposure 
and processed for western blotting as previously described 
[58]. Quantification of protein amounts was performed 
comparatively to alpha beta tubulin expression with 
ImageJ software (http://imagej.nih.gov). These measures 
were then normalized according to the control sample and 
expressed as means +/- SD obtained from replicates of two 
independent experiments.
Immunohistochemistry (IHC) and 
immunocytofluorescence
FFPE tumor samples from patients were gathered 
on a tissue-microarray (TMA) block using a tissue 
arrayer (MTA BOOSTER 01 V2.04, Excilone, France) 
with 3 representative areas selected per tumor. IHC was 
performed using an automated tissue staining system 
(Ventana Medical Systems, Inc., Tucson, AZ, USA). Two 
pathologists analyzed protein expression independently. 
The scoring system was combining the degree of positivity 
and the proportion of positive cells. Indeed, more than 
50% positive tumor cells and a moderate to strong 
intensity were defining an over-expressed protein in our 
samples. PTEN analysis, as well as H3K27m3 staining, 
was considering as a loss, when no protein expression was 
detected in tumor cells on the slides. The cell lines were 
cultured on Lab-Tek Chamber Slide™ Systems (Thermo 
Fisher Scientific, Waltham, USA) until 60% confluence 
and processed for immunocytofluorescence staining as 
previously described [35, 36, 57].
RNA analyses
siRNA transfection
Pre-designed small interfering RNAs (siRNA) 
duplexes against HIF-1α and HIF-2α were purchased 
from Qiagen (Courtaboeuf, France). Cells were 
transfected using Lipofectamine RNAiMAX (Invitrogen, 
Life Technologies, St Aubin, France) according to the 
manufacturer's instructions. Two different siRNAs were 
tested alone or in combination for each target, as well 
as a scrambled sequence control duplex. The efficacy 
of transfection was confirmed with RT-PCR on RNAs 
extracts and immunoblotting on protein extracts made 
at 48 h post-transfection. The effect on proliferation was 
determined using crystal violet viability assay at 24, 48 
and 72 h post-transfection.
mRNA expression profiling analyses
Expression profiling of 5 pHGGs, compared to 
10 pilocytic astrocytomas and 4 grade 1 gliomas, was 
performed. Those 2 DIPGs, 2 thalamic and 1 hemispheric 
pHGG are including in our whole cohort of 26 patients. 
The cell lines (KNS42, SF188 and UW479) were analyzed 
in normoxia and hypoxia conditions at different treatment 
checkpoints: before any treatment, after 24h treatment 
exposure with rapamycin (10 nM), irinotecan (5 μM) 
and both drugs. All those experiments were performed 
in duplicate. Gene expression analysis was performed 
using Affymetrix U133 Plus 2.0 chips. Data were read 
with the affy package and normalized with rma. Gene 
expression was annotated with ensembl genes from build 
37 assembly 71.
DNA analyses of semi-quantitative PCRs 
(qPCRs) and gene sequencing
H3F3A, HIST1H3B, PIK3CA, IDH1, BRAF and 
PDGFRA genes were directly sequenced with a standard 
Sanger technique. Microsatellite analyses were performed 
for PTEN and TP53 genes. qPCRs were performed for the 
determination of copy number alterations of PDFGRA and 
MET comparatively to APP and DCK reference genes. All 
these techniques were performed as previously described 
[58, 59].
HRMAS NMR spectroscopy
HRMAS NMR spectroscopy was performed for 
KNS42, SF188 and UW479 in normoxic and hypoxic 
conditions of proliferation and after 24h exposure with 
rapamycin (10 nM), irinotecan (5 μM) and both drugs. Six 
replicates for each condition were analyzed. For cell lines, 
a pellet of 107 cells was collected and directly snap-frozen 
in liquid nitrogen. HRMAS NMR spectra were analyzed 
on a Bruker Avance III 500 spectrometer operating at a 
proton frequency of 500.13MHz. HRMAS NMR data 
acquisition and spectra processing were performed as 
previously described [60, 61]. A one-dimensional (1D) 
proton spectrum was acquired for each sample. The 
chemical shift was referenced to the peak of the methyl 
proton of L-lactate at 1.33 ppm. Two-dimensional (2D) 
homonuclear and heteronuclear experiments were also 
recorded in order to confirm resonance assignments. 
The quantification procedure was based on the pulse 
length-based concentration measurement (PULCON). 
Spectra were normalized according to each sample weight 
and calibrated using the signal intensity of a 19.3 nmol 
reference solution of lactate. Quantification results were 
expressed as nmol/mg of tissue. Metabolites were assigned 
using standard metabolite chemical shift tables [60–62].
Statistical analyses
GI50 and combination indexes (CI) were 
determined according to the Chou & Talalay method, 
using the Calcusyn software (Biosoft®, Cambridge, 
UK). A CI greater than 1.2 means was considered as a 
drug antagonism, a CI less than 0.8 as a drug synergism 
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and, when it was comprised between 0.8 and 1.2, it was 
concluded as an additive effect.
For mRNA expression profiling, a significant 
differential expression was assigned as a 2 fold up and a 
2 fold down in comparison with control. Up and down-
regulated genes were determined for each drug versus a 
control (untreated cell lines) in normoxic and hypoxic 
conditions. Comparisons were performed between 
hypoxic and normoxic controls for each cell line, but also 
between each treatment condition (irinotecan, rapamycin 
and combination of rapamycin plus irinotecan). Genomic 
data were clustered as a whole and separately for each 
cell line, using standard un-supervised and supervised 
analyses. Gene-set enrichment analyses (GSEA) were 
performed for detection of activated pathways.
A multivariate network based method, the Algorithm 
to Determine Expected Metabolite Level Alterations 
Using Mutual Information (ADEMA), was used to 
assess the changes in metabolite concentrations of NMR 
HRMAS spectroscopy analyses. The algorithm was 
predicting the changes in levels of metabolites between 
the cases and the control using mutual information. We 
determined the relevant metabolites and grouped them 
using the metabolic network topology provided in Kyoto 
Encyclopedia of Genes and Genomes (KEGG) [62, 63] 
and the metabolic atlas by Selway et al. [64]. We used 6 
discrete metabolite levels and probabilistically assigned an 
observation to at most 4 levels. We ran ADEMA 18 times 
with the 6 tested cases comparing the 3 cell lines (SF188, 
KNS42 and UW479) in two conditions of culture (hypoxia 
and normoxia). The metabolic profiles of the controls were 
compared to the metabolic profiles of the cells treated with 
irinotecan, rapamycin and the combination of both drugs 
in both normoxic and hypoxic conditions.
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